BEIGF:OTCMKTS
BeOne Medicines
21,95 $
0,00%
(0,00) 1D
9 հնս, 12:49:46 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
42,86 մլրդ
Avg. vol.
0,00
Volume
0,00
52-wk high
24,92 $
52-wk low
21,95 $
Beta
0,84
Shares outstanding
1,43 մլրդ
No. of employees
12 հզր
Mkt. cap
42,86 մլրդ
Avg. vol.
0,00
Volume
0,00
52-wk high
24,92 $
52-wk low
21,95 $
Beta
0,84
Shares outstanding
1,43 մլրդ
No. of employees
12 հզր
News stories
From web sources and news partners
MarketBeat
·
27 րոպե առաջ
ProKidney (NASDAQ:PROK) Stock Price Down 6% - Here's Why
Stocktwits
·
1 ժամ առաջ
UNH Stock Outpaces S&P 500 In 2026, Eyes Best Year Since Pandemic — CFO Says Wall Street May Be Missing 2027 Upside
Seeking Alpha
·
55 րոպե առաջ
It Might Not Be Over Soon: A Decade Of Explosive Growth In The Options Market
Yahoo Finance
·
1 ժամ առաջ
Stock Market: Will S&P 500 Open Up or Down Today?
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 հզր
Founded28 հոկ, 2010 թ.
Headquarters-
Sector-
Websitebeonemedicines.com